Metamodix has developed a drug-free, nonsurgical device therapy called the EndoSleeve™ intended to eliminate symptoms and reduce weight in patients with Type 2 Diabetes and obesity. The company positions the EndoSleeve as a minimally invasive alternative to surgical interventions. Founded in 2009 and led by CEO Kedar Belhe, PhD, MBA, Metamodix is based in Minneapolis, MN. The business is advancing from development toward clinical testing and plans to complete a first-in-man clinical trial of EndoSleeve using recent financing. The articles do not disclose operating metrics such as revenue or user numbers. MetaModix is a Minnesota medical device company developing an intestinal liner implant intended as a Type 2 diabetes treatment. The device would be placed during an outpatient procedure while the patient is consciously sedated, similar to a gastrointestinal endoscopy. According to the company website, ‘‘resolution of Type 2 diabetes’’ could occur within days of placement and patients could return to normal eating habits within several days while still losing weight. The company says a second‑generation liner that can stay in the body longer may be on the horizon, and groundwork is being laid for U.S. approval of the first‑generation device. Founder and CEO is Kedar Belhe, and directors listed on the filing include Belhe and Manish Parikh. The article discloses no revenue or user metrics.

Total raised

$2M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2015